Incretin‐Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists—A Review
ABSTRACT Background Alzheimer's disease (AD) and Parkinson's disease (PD) are progressive neurodegenerative disorders with significant cognitive and motor impairments, affecting millions globally. Current treatments offer limited efficacy, prompting the exploration of new therapeutic appro...
Saved in:
Main Authors: | Ousman Mohammed, Tsehayneh Kelemu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-07-01
|
Series: | Health Science Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/hsr2.71065 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rikkunshito prevents blood glucose intolerance in rats undergoing distal pancreatectomy
by: Hiroshi Kono, et al.
Published: (2025-12-01) -
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01) -
Physiology and clinical applications of GIP
by: Shunsuke Yamane, et al.
Published: (2025-07-01) -
Neuroprotective effects of essential oils in animal models of Alzheimer’s and Parkinson’s disease: a systematic review
by: Adrielle do Espírito Santos Macedo, et al.
Published: (2025-07-01) -
Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
by: T. Y. Demidova, et al.
Published: (2022-03-01)